CT.gov Hiddenness Atlas
2026-03-29 | full-registry audit | plots, figures, and E156 bundle
E156 Micro-Paper

CT.gov Hiddenness Atlas

A 156-word account of where sponsor-specific opacity, missing results, and structural sparsity concentrate across the live ClinicalTrials.gov registry.

578,109 total studies
249,507 eligible older studies
72.7% 2-year no-results
Paper + dashboard + protocol

Paper

Which sponsor groups account for the largest registry-visible non-disclosure burden across ClinicalTrials.gov? We analysed 578,109 registry records downloaded on March 29, 2026, including 441,191 interventional studies and 290,524 closed interventional studies. We derived omission flags for missing results, missing actual completion dates, missing actual enrollment, absent IPD statements, absent publication links, sparse outcomes, and undisclosed stopping reasons, then summarized them by sponsor class, sponsor, and phase. Among closed interventional studies with primary completion at least two years earlier, 72.7 percent still had no posted results, with OTHER_GOV worst on rate at 95.7 percent and OTHER largest on volume at 127,704 studies. Industry still carried 44,007 two-year no-results studies, phase I had the highest non-reporting rate at 76.7 percent, and NIH had the highest average hiddenness score among named sponsor classes. Registry opacity is concentrated differently by class, so rates, volumes, and structural missingness must be read together. These measures capture registry-visible omission rather than legal violation.

Total studies
578,109
Live registry
Interventional
441,191
Study type
OTHER stock
127,704
2-year no-results
Industry stock
44,007
2-year no-results
Sentence Structure

Question: Which sponsor groups account for the largest registry-visible non-disclosure burden across ClinicalTrials.gov?

Dataset: We analysed 578,109 registry records downloaded on March 29, 2026, including 441,191 interventional studies and 290,524 closed interventional studies.

Method: We derived omission flags for missing results, missing actual completion dates, missing actual enrollment, absent IPD statements, absent publication links, sparse outcomes, and undisclosed stopping reasons, then summarized them by sponsor class, sponsor, and phase.

Primary result: Among closed interventional studies with primary completion at least two years earlier, 72.7 percent still had no posted results, with OTHER_GOV worst on rate at 95.7 percent and OTHER largest on volume at 127,704 studies.

Robustness: Industry still carried 44,007 two-year no-results studies, phase I had the highest non-reporting rate at 76.7 percent, and NIH had the highest average hiddenness score among named sponsor classes.

Interpretation: Registry opacity is concentrated differently by class, so rates, volumes, and structural missingness must be read together.

Boundary: These measures capture registry-visible omission rather than legal violation.